CRBSI market to top $2.11B by 2030

The catheter-related bloodstream infection market is projected to grow from $1.62 billion in 2025 to $1.71 billion in 2026, then reach $2.11 billion by 2030. Growth is being driven by hospital-acquired infections, higher healthcare spending and broader use of infection-control tools.

Why it matters: - Catheter-related bloodstream infections remain a serious hospital complication that can lead to sepsis and other severe outcomes if not diagnosed and treated quickly. - The market outlook points to sustained demand for prevention, diagnosis and treatment tools as hospitals try to reduce infection risk and lower long-term costs.

What happened: - The Business Research Company released its Catheter-Related Bloodstream Infection Global Market Report 2026, covering market size, trends and forecasts through 2035. - The report says the CRBSI market will rise from $1.62 billion in 2025 to $1.71 billion in 2026. - The market is expected to reach $2.11 billion by 2030. - The report describes North America as the largest regional market in 2025.

The details: - CRBSI occurs when bacteria or fungi enter the bloodstream through a catheter used to deliver medications or nutrients. - The report links recent growth to higher use of central venous catheters, more hospital-acquired infections, wider adoption of antibiotic lock therapy, more intensive care capacity and improved clinical awareness. - The forecast period is driven by greater investment in infection prevention protocols, rising demand to manage antimicrobial resistance, growth in hospital infection-control programs, broader use of combination therapies and advances in diagnostics. - Key trends include advanced antimicrobial lock solutions, more infection surveillance, a stronger focus on hospital-acquired infection prevention, expansion of combination antimicrobial therapies and earlier diagnosis. - The report says hospital-acquired infections are a major market driver because catheter-related infections account for a meaningful share of device-related HAIs. - In September 2025, US National Library of Medicine data showed antimicrobial-resistant organisms accounted for 6.6% of infections in 2024. - The same data set found about one-third of HAIs were associated with medical devices. - The prevalence of central line-associated bloodstream infections doubled to 0.4%, according to the cited data. - Rising healthcare spending is also supporting the market by funding prevention, staff training, monitoring systems and faster treatment. - The US Centers for Medicare & Medicaid Services said in December 2024 that US healthcare spending grew 7.5% in 2023 to $4.9 trillion, or about $14,570 per person. - The report also covers Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated technology and trend analysis. - The report offers a free sample at the sample request page. - The full report is available at the market report page.

Between the lines: - The forecast suggests the CRBSI market is benefiting from both clinical need and broader health system spending, not just a single product cycle. - The emphasis on surveillance, early diagnosis and antimicrobial resistance shows the market is moving toward prevention-focused care rather than treatment alone. - North America's lead likely reflects mature hospital infrastructure and high catheter use, while other regions may offer growth as infection-control programs expand.

What's next: - The report points to continued demand for antimicrobial lock solutions, combination therapies and diagnostic tools through 2030. - Hospitals are likely to keep investing in infection-control programs as HAIs and antimicrobial resistance remain pressure points. - The Business Research Company says the next wave of market reporting will emphasize forecasting dashboards, hotspots analysis and future trend tracking.

The bottom line: - CRBSI is a small but growing healthcare market shaped by rising infection-control needs, higher spending and stronger demand for earlier intervention.